Creative Planning
MLYS icon

Creative Planning’s Mineralys Therapeutics MLYS Stock Holding History

Creative Planning’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$788K Buy
29,215
+4,914
+20% +$135K ﹤0.01% 2846
2026
Q1 		$658K Buy
24,301
+3,198
+15% +$93.8K ﹤0.01% 2807
2025
Q4 		$766K Sell
21,103
-1,192
-5% -$47.8K ﹤0.01% 2488
2025
Q3 		$845K Sell
22,295
-2,566
-10% -$55.5K ﹤0.01% 2277
2025
Q2 		$336K Buy
+24,861
New +$360K ﹤0.01% 2800
2025
Q1 		– Sell
-77
Closed -$948 – 3634
2024
Q4 		$948 Buy
+77
New +$1.01K ﹤0.01% 3525

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Creative Planning's MLYS Position: Q2 2026 in Review

Creative Planning increased its Mineralys Therapeutics (MLYS) stake by 20% in Q2 2026, buying an estimated $135K and bringing the position to 29,215 shares worth $788K. The position accounts for ﹤0.01% of the portfolio, ranked #2846.

Creative Planning first reported a position in MLYS in Q4 2024 and has held it in 6 quarters since. The position peaked at $845K in Q3 2025. 224 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Creative Planning held 29,215 shares of Mineralys Therapeutics worth $788K as of Q2 2026.
  • Creative Planning bought 4,914 Mineralys Therapeutics shares in Q2 2026, an estimated $135K.
  • Mineralys Therapeutics made up ﹤0.01% of Creative Planning's portfolio in Q2 2026, its #2846 holding.
  • Creative Planning first reported a position in Mineralys Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Creative Planning's Mineralys Therapeutics position peaked at $845K in Q3 2025.
  • 224 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Creative Planning's 13F filing for Q2 2026, filed 13 Aug 2026.